Retatrutide
While semaglutide and tirzepatide quiet the "food noise," retatrutide goes further — it activates three hormonal pathways (GIP, GLP-1, and glucagon) to suppress appetite, improve insulin sensitivity, AND actively increase fat burning. Early trials show ~24% body weight loss in under a year.
Interested in Retatrutide?
Our medical team will evaluate if this medication is right for you during your consultation.
Dosage & Administration
Weekly subcutaneous injections for 12+ weeks with gradual dose escalation. Dose range: 2-12mg once weekly; 12mg is the maximum maintenance dose. Keep refrigerated.
Important: Like any prescribed medication, dosing varies from person to person. Always follow the dosage prescribed by your healthcare provider. Optimize 360 personalizes every protocol based on your labs, symptoms, and goals.
Side Effects
- GI Effects: Nausea, diarrhea, and decreased appetite — similar to other GLP-1 medications.
- Increased Heart Rate: Because the glucagon component increases metabolic rate, some patients notice mild heart rate elevation.
- Injection Site Reactions: Mild redness or discomfort.
Because retatrutide "turns up the energy" in your body, side effects can be slightly different than pure GLP-1 medications.
Why Choose Optimize 360 for Retatrutide
- Prescribed and monitored by Dr. Steve Farmer — 30+ years in hormone medicine
- Comprehensive lab work before prescribing — we never guess
- Sourced from licensed U.S. compounding pharmacies
- Transparent pricing — the price above is what you pay, no hidden fees
- Telehealth available nationwide — medications shipped to your door
- Unlimited messaging with your provider throughout treatment
Get Started Today
No memberships. No referral needed. Schedule your consultation and we'll take it from there.
Related
How Retatrutide Works
Retatrutide is a novel triple-agonist peptide that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism represents an advancement beyond dual-agonists like tirzepatide. GLP-1 activation reduces appetite and slows gastric emptying. GIP activation enhances insulin secretion and may improve fat metabolism. Glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation — a mechanism not present in other incretin-based therapies. Together, these three pathways create a powerful metabolic effect.
Benefits & Clinical Evidence
Phase 2 clinical trial results for retatrutide showed unprecedented weight loss — participants lost an average of 24.2% of body weight at the highest dose over 48 weeks, making it the most effective weight loss agent studied to date. Beyond weight reduction, the glucagon receptor activation promotes liver fat clearance, which is significant for patients with non-alcoholic fatty liver disease (NAFLD). Metabolic improvements in blood glucose, insulin resistance, blood pressure, and lipid profiles were observed across all dose groups. Phase 3 trials are ongoing.
Who Is a Good Candidate?
Retatrutide may be appropriate for patients with obesity (BMI 30+) or overweight (BMI 27+) with metabolic comorbidities who have not achieved adequate results with lifestyle changes alone or with other GLP-1 medications. Patients who have plateaued on semaglutide or tirzepatide may benefit from retatrutide's additional glucagon receptor mechanism. It may also be considered for patients with significant NAFLD or metabolic syndrome. Medical evaluation including metabolic labs, liver function, and cardiovascular assessment is required before starting therapy.
What to Expect: Treatment Timeline
Appetite reduction is typically noticed within the first week. Significant weight loss begins within the first month, with many participants losing 5-8% of body weight by 12 weeks in Phase 2 trials. Individual results may vary.. The glucagon receptor activation may contribute to increased energy expenditure that patients notice as a subtle increase in metabolic rate. Weight loss continues progressively over 6-12 months. Dosing starts low and is titrated upward gradually to minimize GI side effects. Administered as a once-weekly subcutaneous injection. Available at Optimize 360 from $350/vial.
Side Effects & Safety
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and decreased appetite — consistent with the GLP-1 class. These effects are typically most pronounced during dose titration and improve over time. Slow dose escalation is the primary strategy for minimizing GI symptoms. The glucagon component may theoretically affect blood glucose differently than pure GLP-1 agonists, requiring monitoring in diabetic patients. Heart rate and blood pressure should be monitored. As retatrutide is still in clinical trials, long-term safety data continues to accumulate.
Frequently Asked Questions
A: Semaglutide (Ozempic/Wegovy) activates only GLP-1 receptors. Tirzepatide (Mounjaro/Zepbound) activates GLP-1 and GIP receptors. Retatrutide activates all three — GLP-1, GIP, and glucagon receptors. The additional glucagon receptor activity increases energy expenditure and liver fat clearance, which may explain its superior weight loss results in clinical trials.
A: Retatrutide is not yet FDA-approved. It is currently in Phase 3 clinical trials. At Optimize 360, it is available as a compounded peptide prescribed under medical supervision for eligible patients. Your provider will discuss the current evidence and regulatory status as part of your informed consent process.
A: Yes, many patients transition from other GLP-1 medications to retatrutide, particularly if they have plateaued or want to try the triple-agonist mechanism. Your provider will manage the transition, including appropriate washout timing and dose titration to minimize side effects.
Also Available